Evidence map›Paper›PMID 42140666›Full record

ReviewCardiovascular research2026

The aorta in Marfan syndrome: from molecular mechanisms to mechanobiological dysfunction.

Jay D Humphrey, Dianna M Milewicz

Abstract readReview
In one paragraph

Review in Cardiovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Growth arrest of thoracic aortic aneurysms in aging Marfan mice.American journal of physiology. Heart and circulatory physiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Jay D HumphreyDepartment of Biomedical Engineering, Yale University, New Haven, CT, 06511  USA.ORCID 0000-0003-1011-2025
Dianna M MilewiczDivision of Medical Genetics, Department of Internal Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, 77030  USA.ORCID 0000-0002-7806-0068

Funding

TGFb-Dependent Cell-Matrix Interactions in Thoracic AortopathyP01HL169168 · NHLBI · YALE UNIVERSITY · PI Jay D. Humphrey · 2025 to 2026
$7.4M
Novel genetic Insight into the molecular pathogenesis of atherosclerosisR01HL146583 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MILEWICZ, DIANNA M · 2019 to 2022
$2.6M
ELUCIDATING MECHANISMS OF THORACIC AORTOPATHY VIA COMPUTATIONAL MODELINGR01HL169147 · NHLBI · YALE UNIVERSITY · PI Jay D. Humphrey, George Tellides · 2024 to 2026
$2.0M
American Heart Association-American Stroke AssociationJohn RitterLeducq FoundationMarfanNHLBI NIH HHS P01 HL169168NHLBI NIH HHS R01 HL146583NHLBI NIH HHS R01 HL169147NIH HHS P01 HL169168NIH HHS R01 HL146583NIH HHS R01 HL169147Remembrin' Benjamin Foundations
6 · The paper itself

Abstract

Marfan syndrome (MFS) is an autosomal dominant connective tissue disorder that affects cardiovascular, musculoskeletal, and ocular tissues, with premature death often resulting from dissection of the thoracic aorta. MFS results from pathogenic variants in FBN1, which encodes fibrillin-1, a glycoprotein that promotes elastic fibre organization and stability and contributes to smooth muscle cell mechano-sensing of extracellular matrix. It has been 35 years since the discovery that FBN1 variants cause MFS, yet understanding links between a variant and thoracic aortic disease remains incomplete, and definitive treatments remain wanting. We review advances in understanding disease progression in the aorta in MFS from perspectives of genetics, histology, mechanobiology, and biomechanics, with a focus on mouse models that include further genetic modifications to assess factors contributing to disease progression as well as effects of pharmacological treatments. This monogenic disease results in hundreds of differentially expressed genes in the aorta, many cell specific, that should be delineated as protective compensations, pathologic consequences, or neutral changes, and therapies should promote beneficial compensations and prevent detrimental consequences. Given the complexity of aortic disease in MFS, data-informed and data-driven computational models promise to help integrate multimodal data and increase understanding of molecular and cellular changes that drive disease progression, with a goal of improved therapies that prevent disease progression.

Indexed as

Aorta, ThoracicAortic Aneurysm, ThoracicMarfan SyndromeMechanotransduction, CellularVascular StiffnessAdipokinesAnimalsDisease Models, AnimalDisease ProgressionDissection, Thoracic AortaFibrillin-1Genetic Predisposition to DiseaseHumansMutationPhenotypeVascular RemodelingAdipokinesFBN1 protein, humanFibrillin-1fibrillin-1Gene expressionHomeostasisMarfanMechanotransductionStiffness

Identifiers

PMID42140666
PMCPMC13459826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.